Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v2.4.0.6
CONSOLIDATED BALANCE SHEETS (USD $)
Dec. 31, 2012
Dec. 31, 2011
ASSETS    
Cash $ 782 $ 108,019
Due from Triumph Capital    100
Prepaid expenses    192
Total current assets 782 108,311
Fixed assets - net 1,496 1,132
Total Assets 2,278 109,443
LIABILITIES & STOCKHOLDERS' EQUITY    
Accounts payable 298,994 207,660
Accrued interest payable 159,355 87,411
Notes payable - current - related parties 390,915 191,260
Notes payable - current 225,136 86,000
Note discount (38,072)   
Notes payable - 8% Debenture    30,000
Notes payable - equity obligation payable 463,037   
Stock subscription payable - current 26,000   
Related party payables 351,310 288,448
Other payables 158,006 158,006
Total current liabilities 2,034,681 1,048,785
Notes payable - related parties 363,888 549,263
Total Liabilities 2,398,569 1,598,048
Stockholders' Equity    
Common stock, $.00001 par value; 100,000,000 shares authorized; 25,471,672 (2011) and 30,315,554 (2012) shares issued and outstanding 303 254
Additional paid in capital 11,903,279 9,266,959
Deficit accumulated during the development stage (14,274,244) (10,720,938)
Total TransBiotec, Inc. stockholders' equity (2,370,662) (1,453,725)
Noncontrolling interest (25,629) (34,880)
Total Stockholders' Equity (2,396,291) (1,488,605)
Total Liabilities and Stockholders' Equity $ 2,278 $ 109,443